

peting continuation cooperative agreements in response to this RFA. An applicant may request a project period of up to five years. Because the nature and scope of the research proposed may vary, it is anticipated that the size of each award will also vary. The NCI policy that R01 and U01 applications cannot exceed an increase of 20% over the direct cost award level in the last non-competing (type 5) year does not apply to the applications received in response to this RFA. Although the financial plans of the NCI provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.

**Contact:** The Letter of Intent is to be sent to Dr. Louise B. Grochow Chief, Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Treatment and Diagnosis National Cancer Institute Executive Plaza North, Room 7131 6130 EXECUTIVE BLVD MSC 7426 BETHESDA, MD 20892-7432 Telephone: (301) 496-1196 FAX: (301) 402-0428 E-mail: grochowl@ctep.nci.nih.gov The PHS 398 research grant application instructions and forms (rev. 5/2001) at <http://grants.nih.gov/grants/funding/phs398/phs398.html> must be used in applying for these cooperative agreements. This version of the PHS 398 is available in an interactive, searchable format. For further assistance contact GrantsInfo, Telephone 301/435-0714, Email: GrantsInfo@nih.gov.

**Deadline:** Letter of Intent Receipt Date: February 14, 2002. Application Receipt Date: March 21, 2002.

#### **COOPERATIVE PLANNING GRANT FOR CANCER DISPARITIES RESEARCH PARTNERSHIP: RFA-CA-02-002**

**Purpose:** The National Cancer Institute (NCI) invites cooperative planning grant applications (using the U56 mechanism) in an effort to strengthen the national cancer program by developing models to reduce significant negative consequences of cancer disparities seen in certain U.S. populations. This grant will support the planning, development and conduct of radiation oncology clinical research trials in institutions that care for a disproportionate number of medically underserved, low income, ethnic and minority populations but have not been traditionally involved in NCI-sponsored research. The grant will also support the planning, development and implementation of nurturing partnerships between applicant institutions and committed and experienced institutions actively involved in NCI-sponsored cancer research. All approaches to planning are encouraged, as long as they address the following essential features: a focus on cancer disparities, radiation oncology clinical research, institutional commitment, organizational capabilities, facilities, and interdisciplinary coordination and collaboration. At this time, NCI anticipates issuing another RFA for the establishment of

additional Cancer Disparities Research Partnerships in fiscal year 2003.

**Term/Amount:** NCI/RRP anticipates making up to three 5-year grant awards in fiscal year 2002. NCI also anticipates issuing another RFA for the establishment of additional CDRPs in fiscal year 2003. The NCI/RRP plans to set aside \$2.1 million for the initial year's funding that includes direct costs, costs for facilities and administration, and one-time capital equipment costs. Excluding one-time capital costs expended in the first year, applicants may request a budget for direct costs of up to an average of \$400,000 per year over the five years of the grant. Because the nature and scope of research and partnerships may vary, it is anticipated that the size of each award will also vary.

**Contact:** The letter of intent is to be sent to Referral Officer Division of Extramural Activities 6116 Executive Boulevard, Room 8109, MSC 8239 Rockville, MD 20852 (express service) Bethesda, MD 20892-8236 Telephone: (301) 496-3428 Fax: (301) 402-0275 Email: ncidearefof-r@mail.nih.gov The PHS 398 research grant application instructions and forms (rev. 5/2001) at <http://grants.nih.gov/grants/funding/phs398/phs398.html> must be used in applying for these grants. This version of the PHS 398 is available in an interactive, searchable format. For further assistance contact GrantsInfo, Telephone 301/435-0714, Email: GrantsInfo@nih.gov.

**Deadline:** Letter of Intent Receipt Date: February 6, 2002. Application Receipt Date: March 13, 2002.

#### **GEORGE M. O'BRIEN KIDNEY RESEARCH CENTERS: RFA-DK-02-028**

**Purpose:** This Request for Applications (RFA) invites investigators to submit research applications for the George M. O'Brien Kidney Research Centers Program. The emphases for this program are fourfold (1) to continue to attract new scientific expertise into the study of the basic mechanisms of kidney diseases and disorders; (2) to encourage multidisciplinary research focused on the causes of these diseases; (3) explore new basic areas that may have clinical research application; and (4) generate \*Developmental Research (DR)/Pilot and Feasibility (P&F) studies of two years duration, which are anticipated will lead to new and innovative approaches to study kidney disease, and the eventual submission of competitive investigator-initiated R01 research grant applications. The mounting complexities associated with the studies of disease processes will likely require investigators who have training and expertise in disciplines such as cell and molecular biology, biochemistry, physiology, genomics and proteomics, epidemiology, immunology and pathology. In addition, appropriate expertise will likely include a focus into topical areas, such as diabetic nephropathy or other

endocrine and metabolic disorders; hypertension in kidney disease; hereditary renal disease; immunologic renal disease; acute renal failure and nephrotoxic cell injury. Individual institutions with both basic and clinical research capabilities are eligible to apply. Inter-institutional collaborative research arrangements are also appropriate and encouraged. Coordination for such arrangements must be evident and clearly meaningful and appropriate for the research proposed. \*Generally DR/P&F proposals are expected to have limited preliminary data and are reviewed based on the clear development of hypotheses and supporting literature.

*Term/Amount:* The NIDDK intends to provide sufficient funds in FY 2003 to fund three (3) new and/or competing continuation center grants in response to this RFA. Three competing continuation applications are anticipated in response to this RFA. New or competing renewal O'Brien Kidney Research Center applications may request maximum annual direct costs of \$700,000 (not to exceed \$3.5 million for five years). For renewal applications, budgets requested for research subprojects and core facilities are limited to 20% budget growth over the most recent non-competing budget. Both new and renewal applications must include budgets of \$120,000 annually for Developmental Research/Pilot and Feasibility (P&F) projects. The direct cost cap of \$700,000, however, can be exceeded by the Facilities and Administrative (F&A) Costs (previously referred to as "indirect costs") on consortia subcontracts to other participating institutions. The budgets of these consortia subcontracts may include the regular cost-of-living increases (currently 3% per year). Because the nature and scope of the research proposed may vary, it is anticipated that the size of each award will also vary. Although the financial plans of the NIDDK provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds in FY 2003 and the receipt of a sufficient number of applications of outstanding scientific and technical merit.

*Contact:* The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Activities, NIDDK 6707 Democracy Boulevard, Room 752 MSC 5452 Bethesda, MD 20892-5452 (for express/courier service: Bethesda, MD 20817) Telephone: (301) 594-8897 FAX: (301) 480-3505 APPLICATION PROCEDURES The PHS 398 research grant application instructions and forms (rev. 5/2001) at <http://grants.nih.gov/grants/funding/phs398/phs398.html> are to be used in applying for these grants. This version of the PHS 398 is available in an interactive, searchable PDF format. Beginning January 10, 2002, however, the NIH will return applications that are not submitted on the 5/2001 version. For further assistance

contact GrantsInfo, Telephone 301/435-0714, Email: GrantsInfo@nih.gov.

*Deadline:* Letter of Intent Receipt Date: May 21, 2002. Application Receipt Date: June 19, 2002.

#### **INTERACTION OF GENES AND ENVIRONMENT IN SHAPING RISK FACTORS FOR HEART, LUNG, BLOOD, AND SLEEP DISORDERS: RFA-HL-02-010**

*Purpose:* Applications are being sought to identify novel genes which interact with specific environmental exposures to modify risk factors for heart, lung, blood, and sleep (HLBS) disorders. The genetic aspects of response to environmental change, and related biological mechanisms, will be studied using short term, focused interventions in families. The goal of this Request for Applications (RFA) is to identify subgroups based on genotype who are most likely to benefit from targeted environmental changes designed to reduce the development or progression of HLBS diseases.

*Term/Amount:* The NHLBI intends to commit approximately \$9,000,000 in FY 2002 to fund 3 to 5 new grants in response to this RFA. Up to \$36,000,000 (total cost) over the entire project period is available to support this initiative. Because the nature and scope of the research proposed may vary, it is anticipated that the size of each award will also vary. Although the financial plans of the NHLBI provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. At this time, there is no plan to reissue this RFA.

*Contact:* The letter of intent is to be sent to Deborah Beebe, Ph.D. Division of Extramural Affairs National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room 7178, MSC 7924 Bethesda, MD 20892-7924 Telephone: (301) 435-0270 FAX: (301) 480-3541 Email: beebed@nhlbi.nih.gov The PHS 398 research grant application instructions and forms (rev. 5/2001) at <http://grants.nih.gov/grants/funding/phs398/phs398.html> are to be used in applying for these grants. This version of the PHS 398 is available in an interactive, searchable PDF format. Beginning January 10, 2002, the NIH will return applications that are not submitted on the 5/2001 version. For further assistance contact GrantsInfo, Telephone 301/435-0714, Email: GrantsInfo@nih.gov.

*Deadline:* Letter of Intent Receipt Date: February 20, 2002. Application Receipt Date: March 22, 2002.

#### **CENTERS FOR REDUCING ASTHMA DISPARITIES: RFA-HL-02-006**

*Purpose:* The objective of this program is to promote partnerships (to be called Centers) between a minority